West Pharmaceutical Services, I – Consensus Indicates Potential 51.4% Upside
West Pharmaceutical Services, I found using ticker (WST) now have 6 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 449 and 330 with the average target price sitting at 383.17. Now with the previous closing price of 253.11 this would indicate that there is a potential upside of 51.4%. The 50 day moving average now sits at 309.46 and the 200 day MA is 351.67. The market cap for the company is $18,826m. You can visit the company''s website by visiting: https:||www.westpharma.com [stock_market_widget type="chart" template="basic" color="green" assets="WST" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,500m based on the market concensus. West Pharmaceutical Services designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
West Pharmaceutical Services, I – Consensus Indicates Potential 51.4% Upside
West Pharmaceutical Services, I found using ticker (WST) now have 6 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 449 and 330 with the average target price sitting at 383.17. Now with the previous closing price of 253.11 this would indicate that there is a potential upside of 51.4%. The 50 day moving average now sits at 309.46 and the 200 day MA is 351.67. The market cap for the company is $18,826m. You can visit the company''s website by visiting: https:||www.westpharma.com [stock_market_widget type="chart" template="basic" color="green" assets="WST" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,500m based on the market concensus. West Pharmaceutical Services designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.